Tryon Williams
Président chez KIDOZ INC.
Fortune : 4 M $ au 30/04/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Jason Williams | M | 49 | 23 ans | |
Eldad Tora | M | 54 | 11 ans | |
Henry Bromley | M | 53 | 22 ans | |
Fiona Curtis | F | 58 | 15 ans | |
Claes Kalborg | M | 62 | 6 ans | |
Moshe David | M | 59 | 5 ans | |
Lee Groat | M | - |
University of British Columbia
| 21 ans |
Neil Cashman | M | 72 |
University of British Columbia
| 19 ans |
Yossef Av-Gay | M | 62 |
University of British Columbia
| 30 ans |
Michael Hitch | M | - |
University of British Columbia
| 17 ans |
Daniel Pauly | M | - |
University of British Columbia
| 30 ans |
Kevin McElwee | M | 54 |
University of British Columbia
| 20 ans |
R. Scott McKinley | M | 68 |
University of British Columbia
| 23 ans |
Steven Plotkin | M | - |
University of British Columbia
| 23 ans |
David M. Liu | M | 50 |
University of British Columbia
| 16 ans |
Tryon Williams | M | 53 | 5 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Nick Glover | M | 55 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 ans |
Leonard Vernon | M | 80 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Ali Kashani | M | 40 |
University of British Columbia
| 3 ans |
Akio Tanaka | M | 54 |
University of British Columbia
| 6 ans |
Johan Petter Erik Nylander | M | 60 | 1 ans | |
Vanessa Collette | F | - |
University of British Columbia
| 5 ans |
Sebastian Jaimungal | M | - |
University of British Columbia
| 5 ans |
Peeyush Varshney | M | 57 |
University of British Columbia
| 8 ans |
Steve Veitch | M | - |
University of British Columbia
| 5 ans |
Ebba Dagmar Lucie Ljungerud | F | 52 | 4 ans | |
David Phillips | M | - |
University of British Columbia
| 4 ans |
Philip Frost | M | 84 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 ans |
Farzad Forooghian | M | 45 |
University of British Columbia
| 4 ans |
Paul Thomas | M | 50 |
University of British Columbia
| 3 ans |
Helge Seetzen | M | - |
University of British Columbia
| 11 ans |
James Smith | M | 54 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 3 ans |
Wen Chuan Zhou | F | 41 |
University of British Columbia
| 5 ans |
Jeff Hunter | M | - |
University of British Columbia
| 6 ans |
Nick B. Drake | M | - |
University of British Columbia
| 10 ans |
Wale Bolorunduro | M | - |
University of British Columbia
| 4 ans |
Wen Wei Guan | M | 55 |
University of British Columbia
| 5 ans |
Kong Lok Yip | M | 48 |
University of British Columbia
| 5 ans |
Michael Leo | M | 47 |
University of British Columbia
| 6 ans |
Gabriel Fung | M | - |
University of British Columbia
| 7 ans |
Vladimir Cvijetinovic | M | - |
University of British Columbia
| 7 ans |
Hon Sum Sam Jor | M | 42 |
University of British Columbia
| 5 ans |
Frank S. Moyle | M | - |
University of British Columbia
| 9 ans |
Persio Pellegrini Rosario | M | - |
University of British Columbia
| 5 ans |
Ben De Wit | M | - |
University of British Columbia
| 7 ans |
Dong Xiao Qiu | M | 62 |
University of British Columbia
| 5 ans |
Salim Dhanji | M | 44 |
University of British Columbia
| 8 ans |
John Priatel | M | 58 |
University of British Columbia
| 11 ans |
Mouane Sengsavang | F | 47 |
University of British Columbia
| 8 ans |
Derek Hemmes | M | - |
University of British Columbia
| 10 ans |
Li Zhu | F | - |
University of British Columbia
| 3 ans |
Catherine Mackey | M | 68 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 ans |
George Whitton | M | 86 | - | |
Amanda Gale Miller | F | 42 |
University of British Columbia
| 8 ans |
Jacqueline Simpson | F | - |
University of British Columbia
| 11 ans |
Robert E. Cohen | M | - |
University of British Columbia
| 11 ans |
Thomas Ian Alexander Allen | M | 83 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Roger Quick | M | - |
University of British Columbia
| 7 ans |
Henry Friesen | M | 90 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Hans Knapp | M | - |
University of British Columbia
| 3 ans |
Kapil Dhingra | M | 64 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 1 ans |
Claire Huxtable | F | - |
University of British Columbia
| 6 ans |
Shaun Foy | M | - |
University of British Columbia
| 9 ans |
François Thomas | M | 66 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 ans |
Trevor Robinson | M | - |
University of British Columbia
| 18 ans |
Jonathan Bey | M | 54 |
University of British Columbia
| 5 ans |
Christopher Mark Devereux | M | 59 | 16 ans | |
Matthew Hamilton | M | 41 |
University of British Columbia
| 5 ans |
Arie Page | F | 45 |
University of British Columbia
| 8 ans |
Arsalan Farrokh | M | - |
University of British Columbia
| 4 ans |
Mark Kowalski | M | 69 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | - |
Lei Huang | F | 41 |
University of British Columbia
| 4 ans |
Keith Gillard | M | - |
University of British Columbia
| 5 ans |
Glans Graydon | M | 37 |
University of British Columbia
| 4 ans |
Nousheen Huq | F | 53 |
University of British Columbia
| 3 ans |
Wendi V. Rodrigueza | M | 58 |
University of British Columbia
| 3 ans |
Kristina Hess | F | - |
University of British Columbia
| 4 ans |
Yao Yao | M | 35 |
University of British Columbia
| 4 ans |
Jim Chan | M | - |
University of British Columbia
| 4 ans |
Michael Minor | M | - |
University of British Columbia
| 4 ans |
Rajeena Minhas | F | - |
University of British Columbia
| 4 ans |
Adrian Crawford Ansell | M | 65 |
University of British Columbia
| 5 ans |
John Edward Veltheer | M | 58 |
University of British Columbia
| 3 ans |
Asha Reeves | F | 52 |
University of British Columbia
| 4 ans |
Ross Smith | M | 85 |
University of British Columbia
| 6 ans |
Rory Edward North | M | - |
University of British Columbia
| 4 ans |
Ryan Weymark | M | - |
University of British Columbia
| 4 ans |
Brad Peters | M | 51 |
University of British Columbia
| 4 ans |
Michael Shaw | M | - |
University of British Columbia
| 4 ans |
Alvin Cheung | M | - |
University of British Columbia
| 5 ans |
Michael Leung | M | - |
University of British Columbia
| 4 ans |
Colin I. Godwin | M | 84 |
University of British Columbia
| 24 ans |
Tom C. Wach | M | - |
University of British Columbia
| 4 ans |
Chadwick Wasilenkoff | M | - |
University of British Columbia
| 4 ans |
Kevin Cohen | M | - |
University of British Columbia
| 3 ans |
Abdul Farooqi | M | - |
University of British Columbia
| 4 ans |
Wendy Louise Bach | F | 69 |
University of British Columbia
| 3 ans |
Randy Smallwood | M | 59 |
University of British Columbia
| 4 ans |
Jason Ng | M | - |
University of British Columbia
| 4 ans |
Paul McMillan | M | - |
University of British Columbia
| 4 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Canada | 100 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Tryon Williams
- Réseau Personnel